

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **GenFleet Therapeutics (Shanghai) Inc.**

**劲方医药科技(上海)股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2595)**

### **VOLUNTARY ANNOUNCEMENT INCLUSION INTO THE STOCK LIST OF THE STOCK CONNECT PROGRAM (SHANGHAI-HONG KONG STOCK CONNECT AND SHENZHEN-HONG KONG STOCK CONNECT)**

This announcement is made by GenFleet Therapeutics (Shanghai) Inc. (the “**Company**” or “**GenFleet**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest developments updates of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that according to the announcements from the Shanghai Stock Exchange and the Shenzhen Stock Exchange respectively, the Company will be included in the eligible shares list of the Stock Connect Program (the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect) starting from March 9, 2026. The inclusion of the Company’s shares into the Stock Connect Program allows eligible investors in the Chinese Mainland to directly invest in the Company’s shares via the Shanghai Stock Exchange and the Shenzhen Stock Exchange.

The Company will also be included as a constituent of Hang Seng Index Series with the effect from March 9, 2026, including the Hang Seng Composite Index (HSCI), the Hang Seng Stock Connect Hong Kong Index, and the Hang Seng Innovative Drug Index.

#### **About the Stock Connect Program**

The Shanghai Stock Exchange, the Shenzhen Stock Exchange and The Stock Exchange of Hong Kong Limited have established technical connection, enabling investors in the Chinese Mainland and China’s Hong Kong Special Administrative Region to trade eligible stocks listed on each other’s stock exchange through their local securities firms or brokers.

By order of the Board  
**GenFleet Therapeutics (Shanghai) Inc.**  
**Dr. Qiang LU**  
*Chairman and Executive Director*

Hong Kong, March 9, 2026

*As at the date of this announcement, the Board of the Company comprises:(i) Dr. Qiang LU, Dr. Jiong LAN and Ms. ZHANG Wei as executive directors; (ii) Mr. ZHU Jingyang and Ms. TAO Sha as non-executive directors; and (iii) Ms. Christine Shaohua LU-WONG, Dr. ZHOU Demin and Mr. LI Bo as independent non-executive directors.*